About us +
About us
About us
IPPro Life Sciences

The life sciences sector is undergoing a period of intense transformation, facing an ever-increasing level of regulation and having to manage costs in order to remain competitive and maintain profitability.

In the midst of this, pharmaceutical, biotechnology and medical device companies operating internationally are increasingly embroiled in complex multijurisdictional patent litigation. At the same time, increasing pricing pressure is forcing them to lay claim to new and complex branding initiatives as they bid to keep hold or increase their market shares. Added to these are the markets for counterfeit drugs and medical devices that threaten consumer and brand health.

Pharmaceutical companies are also coming to terms with an environment in which generics are on the rise. Money is being poured into research and development, but compulsory licensing and expiring patents mean that work has to be made more efficient and cost effective. Most importantly, new drugs need to get to market more quickly without compromising patient safety.

Meanwhile, new life sciences technology is on the rise, forcing attorneys to find new ways of drafting patent applications so that the broadest amount of coverage is provided unopposed. New clusters of investors, universities, private labs and dedicated legal boutiques are emerging too, ensuring that the needs of new technology are serviced at every level as efficiently and well as possible.

As this complex sector develops and heads in new directions, IPPro Life Sciences will be there to report on these and other major advances, as well as all of the latest news from around the world.

From private practice life sciences groups, to multinational pharmaceutical companies, university labs and venture capitalists, IPPro Life Sciences has something for everyone with an interest in intellectual property and the legal implications for the life sciences sector.

FaceBook LinkedIn RSS feed Blog Instagram Twitter
Specialist Features +
Country Profiles ++
Interviews +++
Matters of import
20 January 2016
Alireza Behrooz of Merchant & Gould and Nick Phillips of Edwin Coe discuss parallel importation of pharmaceuticals in the US and Europe readmore

Raising the bar
16 December 2015
Amendments to the US Civil Rules of Procedure could dissuade some non-practicing entities from targeting technology-rich sectors readmore

Making connections
02 December 2015
Changes are coming to the UK Patent Box to meet new international standards readmore

More features
06 January 2016
Australia’s IP system has come under the spotlight as the government considers possible reforms. Naomi Pearce and Nigel Lokan of K&L Gates speak to Tammy Facey readmore

11 September 2015
Mohan Dewan and Disha Dewan of R K Dewan & Co report on the ban on any changes to patent specifications or claims at the time of national phase entry via the Patent Cooperation Treaty in India readmore

11 September 2015
The fear that natural products would be privatised soon, or one cannot study a product of nature and benefit from it if another legally possesses it, is always in the minds of all stakeholders. D. Calab Gabriel and Maria Gabriel of Lex IP Care discuss the patenting of natural bio-materials in India readmore

More country profiles
Terry Mahn
Fish & Richardson
03 February 2016
Terry Mahn of Fish & Richardson discusses the issues still to be resolved in the Food and Drug Administration’s proposed naming system for biosimilars readmore

Rogelio Nicandro
Romulo LLP
04 November 2015
Rogelio Nicandro of Romulo LLP offers some handy tips for stopping trademark infringement in the Philippines readmore

Grant Shoebridge
Shelston IP
04 November 2015
Grant Shoebridge of Shelston IP unpacks the Australian High Court’s Myriad decision readmore

More interviews
IPPro Life Sciences


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization